Dasatinib Therapy
Reports from Medical University of Vienna, Division of Hematology add new data to research in dasatinib therapy
Published in Blood Weekly, December 10th, 2009
Current study results from the report, 'Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily,' have been published. According to recent research from Vienna, Austria, "The multikinase inhibitor dasatinib exerts growth-inhibitory effects in patients with imatinib-resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable."
"We examined the side effect profile in 16 patients with imatinib-resistant CML who received 140 mg dasatinib daily in our center. Dasatinib produced substantial and sometimes severe or even life-threatening side effects...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-12-10)
More Articles from Blood Weekly
- American College of Radiology / American Roentgen Ray Society
Radiology procedure may help increase long-term survival in patients with severe liver cancer - University of Maryland Medical Center
Tobacco smoke exposure before heart transplantation may increase the risk of transplant failure - Wiley-Blackwell
Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US - Wiley-Blackwell
Drug side effects a key factor in reduced quality of life for kidney transplant patients - Wiley-Blackwell
New data emerges on liver transplant survival rates - Ambit Biosciences Corporation
Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
